Inspire Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Inspire Advisors’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	833
2020 Q4	$0	Buy	+1	New	–	﹤0.01%	833

Other funds holding SVA

SAIF Advisors Admiralty, Hong Kong $438M AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Inspire Advisors's SVA Position: Q1 2021 in Review

Inspire Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q1 2021, closing a stake of 1 share.

Inspire Advisors first reported a position in SVA in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 29 funds tracked by Wall St. Rank hold SVA as of Q1 2021.

Inspire Advisors reported no remaining Sinovac Biotech, Ltd position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 1 Sinovac Biotech, Ltd share in Q1 2021.
Inspire Advisors first reported a position in Sinovac Biotech, Ltd in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Sinovac Biotech, Ltd position peaked at $0 in Q4 2020.
29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.